Olubunmi Afonja, MD, MBASenior Director, Clinical Development at Editas MedicineSpeaker
Profile
Dr. Olubunmi Afonja is Senior Director of Clinical Development at Editas Medicine, Cambridge, MA. She joined Editas Medicine in September 2021 as the medical lead for development activities related to the pipeline of experimental gene therapy medicines for benign hematologic diseases.
Prior to joining the pharmaceutical industry, Dr. Afonja spent 13 years at NYU Lagone Hospital in academic practice, serving as a clinical attending and faculty in the pediatric hematology/oncology program with a focus on benign hematologic diseases.
Dr. Afonja spent approximately 13 years at Bayer during which she worked in drug development in roles within both medical affairs and clinical development, supporting the commerical team in the successful launch of two recombinant FVIII products.
Dr. Afonja received her MBBS at the University of Ibadan, Nigeria. She completed a pediatric residency at SUNY Health Science Center, Brooklyn and post-graduate fellowship training in pediatric hemataology/oncology at NYU College of Medicine. Dr. Afonja obatined her MBA from George Washington University, and is first and co-author on several peer-reviewed publications.
Agenda Sessions
AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 (reni-cel) Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-dependent Beta-thalassemia
, 10:45amView Session